Ventyx Biosciences

Inactive

VTYX (NMS)

Ventyx Biosciences is a clinical-stage biopharma developing oral therapies for autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes NLRP3 inhibitors and other inflammatory modulators such as VTX958 for Crohn’s disease, Tamuzimod for ulcerative colitis, VTX2735 for cryopyrin-associated periodic syndrome, and VTX3232 for early Parkinson’s and obesity-related cardiovascular risk. Founded in 2018 in San Diego, it operates as a subsidiary of Eli Lilly as of March 4, 2026.